Madrigal Pharmaceuticals, Inc. (MDGL)
After hours:
| Previous Close | 235.57 |
| Open | 222.00 |
| Bid | 217.27 x 100 |
| Ask | 218.03 x 100 |
| Day's Range | 214.96 - 230.49 |
| 52 Week Range | 119.76 - 311.56 |
| Volume | |
| Avg. Volume | 566,690 |
| Market Cap | 4.639B |
| Beta (5Y Monthly) | -0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.00 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 377.07 |
- GuruFocus.com
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
First Quarter Performance Highlights and Strategic Updates
GlobeNewswireMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn April 2024, product shipped and first patients received Rezdiffra, the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)On March 5, 2024, announced validation of European Medicines Agency marketing application for resmetirom Raised $690 million in gross p
- GlobeNewswire
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent in
